Table 2.
Univariate analysis of prognostic factors
| Hazard ratio | 95% CI | p-value | |
|---|---|---|---|
| BRAF status | |||
| Positive | 0.345 | 0.163–0.732 | 0.0056 |
| Negative | 1 | ||
| msGPA score | |||
| 0–2 | 1 | ||
| 3–4 | 0.194 | 0.0882–0.428 | <0.0001 |
| Neurological symptoms | |||
| Present | 1.85 | 0.701–4.88 | 0.2141 |
| Absent | 1 | ||
| Age | 1.022 | 0.996–1.048 | 0.0928 |
| Sex | |||
| Male | 1 | ||
| Female | 0.513 | 0.261–1.012 | 0.0541 |
| KPS | |||
| 70–100 | 1 | ||
| <70 | 4.003 | 1.56–10.26 | 0.0039 |
| Extra cranial disease | |||
| Present | 1 | ||
| Absent | 0.912 | 0.397–2.10 | 0.8303 |
| Development of brain mets | |||
| Presentation of metastatic disease | 0.698 | 0.356–1.37 | 0.2941 |
| During treatment for metastatic disease | 1 | ||